HURWITZ EDWARD 4

What Happened Edward Hurwitz, a director of Dyne Therapeutics (DYN), was granted a derivative award on June 5, 2026: options to acquire 35,152 shares. The Form 4 lists the acquisition price as $0.00 (derivative award), so no cash was paid at grant and the reported grant value is $0 on the filing. This is a compensation award (not an open-market purchase or a sale).

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (filed within the required reporting window).
• Transaction type/code: A — grant/award of a derivative security (option).
• Amount: Options covering 35,152 shares; filing shows acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The option vests in full on the earlier of (i) June 5, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Context This was an option grant as part of director compensation — a common, non-market transaction that does not represent an immediate buy or sell signal. The award vests based on continued service (or earlier at the 2027 annual meeting), and there is no indication in the filing that the options were exercised or that any shares were sold.